Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TT 223 + Glucagon-like peptide-1 analogue

Drug Profile

TT 223 + Glucagon-like peptide-1 analogue

Alternative Names: G1 + GLP-1; TT-223 + GLP-1; TT-223 + LY2428757

Latest Information Update: 27 Sep 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Transition Therapeutics
  • Developer Eli Lilly; Transition Therapeutics
  • Class Antihyperglycaemics; Gastrointestinal hormones; Glucagon-like peptides; Neuropeptides; Peptide hormones
  • Mechanism of Action Gastrin stimulants; Glucagon-like peptide 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 17 Sep 2010 Discontinued - Phase-I for Type-2 diabetes mellitus in Puerto Rico (SC)
  • 17 Sep 2010 Discontinued - Phase-I for Type-2 diabetes mellitus in USA (SC)
  • 25 Mar 2009 Eli Lilly and Transition Therapeutics dose the first patient in a phase Ib study of TT 223 in combination with LY 2428757
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top